Understanding how the 26S proteasome recognizes different forms of ubiquitin
Determine the mechanism of recognition of ubiquitin configurations by the 26S proteasome
This study is looking at how a part of our cells called the 26S proteasome recognizes different shapes of a small protein called ubiquitin that helps mark other proteins for breakdown, which is important for understanding diseases like cancer and autoimmune disorders.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard Medical School NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10694205 on NIH RePORTER |
What this research studies
This research investigates how the 26S proteasome, a crucial component in cellular protein degradation, recognizes various configurations of ubiquitin attached to proteins. By examining the specific features of ubiquitin chains, such as their length and arrangement, the study aims to uncover the mechanisms that dictate how proteins are targeted for degradation. The researchers will utilize advanced single-molecule techniques and innovative DNA scaffolds to create and analyze these ubiquitin configurations, providing insights into the proteasome's selectivity and efficiency in degrading proteins. This understanding could have implications for diseases where protein degradation is disrupted, such as cancers and autoimmune disorders.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with conditions related to protein degradation abnormalities, such as specific types of cancer or autoimmune diseases.
Not a fit: Patients with conditions unrelated to protein degradation or those not affected by the ubiquitin-proteasome system may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for diseases linked to protein degradation, including certain cancers and autoimmune conditions.
How similar studies have performed: Previous research has shown success in understanding the ubiquitin-proteasome system, but this specific approach using DNA scaffolds to engineer ubiquitin configurations is relatively novel.
Where this research is happening
Boston, United States
- Harvard Medical School — Boston, United States (Active)
Researchers
- Principal investigator: Lu, Ying — Harvard Medical School
- Study coordinator: Lu, Ying
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.